Gothenburg, Sweden – 11 December 2024 – Atley Solutions announces the first sale, delivery and installation of the Atley C100 to a US based biotech customer. The US represents a key market for Atley and the first delivery to the region represents a major milestone in the launch of the Atley C100 module.
“The first installation of the Atley C100 in the US marks another important commercial milestone for Atley Solutions and is an exceptional achievement by the whole Atley team. The customer is a front runner in our market niche aiming to develop new cancer treatments based on At-211. The Atley C100 installation marks the next phase in our partnership, and we look forward to supporting this customer with their clinical translation in the near future” said Milton Lönnroth, CEO of Atley Solutions.
One Integrated Platform for Purifying At-211 and Manufacturing At-211 radiopharmaceuticals
The Atley C100 is the world’s first commercial module specifically designed for the manufacturing of At-211 (astatine-211) radiopharmaceuticals. The Atley C100 module can both purify At-211 from irradiated cyclotron targets and manufacture At-211-based radiopharmaceuticals in an automated process. As a platform technology, the Atley C100 can be used to develop and manufacture multiple different At-211 radiopharmaceuticals, each focused on different cancer indications. With its CE marking and CB certification in place, the Atley C100 was launched earlier in this year is now available to researchers and drug developers worldwide, offering new possibilities in the field of targeted cancer therapy.
Enabling Next-Generation Metastatic Cancer Treatment
Atley Solutions is committed to making the development of At-211-based radiopharmaceuticals more accessible. With the Atley C100, the company aims to provide researchers and clinicians with a solution to help them explore the potential of At-211-based radiopharmaceuticals and translate research into clinical possibilities. The focus on precision and scalability supports a future where more personalised cancer treatments become part of the standard part of care.
